Comparison of antiviral agents for seasonal influenza outcomes in healthy adults and children: a systematic review and network meta-analysis.

Liu JW, et al. JAMA Netw Open. 2021;4(8):e2119151.

Baloxavir marboxil for uncomplicated influenza in adults and adolescents.

Hayden FG, et al. N Engl J Med. 2018;379(10):913-923.

Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.

Ison MG, et al. Lancet Infect Dis. 2020;20(10):1204-1214.

Baloxavir marboxil single-dose treatment in influenza-infected children: a randomized, double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2).

Baker J, et al. Pediatr Infect Dis J. 2020;39(8):700-705.

Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials.

Dobson J, et al. Lancet. 2015;385(9979):1729-1737.

Efficacy and safety of intravenous peramivir compared with oseltamivir in high-risk patients infected with influenza A and B viruses: a multicenter randomized controlled study.

Nakamura S, et al. Open Forum Infect Dis. 2017;4(3):ofx129.

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections.

Hayden FG, et al. GG167 Influenza Study Group. N Engl J Med. 1997;337(13):874-880.

Acute myocardial infarction after laboratory-confirmed influenza infection.

Kwong JC, et al. N Engl J Med. 2018;378(4):345-353.

Influenza in the COVID-19 era.

Solomon DA, et al. JAMA. 2020;324(13):1342-1343.